Quantity of eligible individuals: CDEC mentioned the uncertainty in the amount of individuals with moderately serious to serious hemophilia B in Canada eligible for etranacogene dezaparvovec. Scientific industry experts consulted by CADTH indicated that some people who will be labeled as having moderate or average illness may have a severe bleeding